ANTIEMETIC ACTIVITY OF 2 DIFFERENT HIGH-DOSES OF METOCLOPRAMIDE IN CISPLATIN-TREATED CANCER-PATIENTS - A RANDOMIZED DOUBLE-BLIND TRIAL OF THE ITALIAN ONCOLOGY GROUP FOR CLINICAL RESEARCH

  • 1 December 1985
    • journal article
    • research article
    • Vol. 69  (12) , 1353-1357
Abstract
High-dose metoclopramide has been proposed as an effective antiemetic agent in patients treated with cisplatin. Its optimal dosage schedule, however, has not yet been completely defined. We report the results of a multicenter, double-blind, randomized clinical trial where the efficacy and safety of two fixed high-dose regimens of metoclopamide (60 and 120 mg, respectively) have been tested in 112 patients receiving cisplatin treatment. No statistically significant difference has been found between the two groups. In patients treated with cisplatin at doses > 100 mg/m2, the higher dose regimen seems more efficacious, but this result should be confirmed in a larger group of patients. Treatment was generaly well-tolerated. however, a consistent percentage of patients (about 60%) still present with vomiting, and this makes further investigation necessary.